Core Concept
Importance of new drug development based on clinically relevant biomarkers


Core Technology
CTA (Clinical-based Target for Antibody Drug) Platform for Efficient Drug Development
CTA Platform

Innovative R&D through precise assessment of target indication
-
C Clinical Unmet Need Based
New Drug DevelopmentClinically Needed Drug
- Pharmaceuticals Needed in Clinic
- Preemptive Clinical Trial Design
- Animal Studies that Mimic Clinical Trials
-
T Target Analysis Based
on Clinical DiseasesTherapeutic Target Selection
- Target Discovery from Patient Tissues
- Disease-Specific Target Analysis
- Target Identification through Drug Responsiveness Prediction
-
A Antibody Development
Antibody therapeutics
- High Affinity & Selectivity for the Target
- High Potency & Productivity
- Monoclonal, Bispecific antibodies, ADCs



-
Biomarker-based diagnostics and therapeutics
-
Animal Studies that Mimic Clinical Trials
-
Clinical Trial monitoring biomarker changes




Innovation
- Market-Leading New Drug
- Pipeline reinforcement
- Global Competitiveness
- Sustainable Growth

Top-tier rating in technology credit assessment


Selection as a baby unicorn company
